The CE approval opens Europe for Cornerstone Robotics as the company expands its global surgical robotics business
Updated
May 29, 2026 4:20 AM
A tray of surgical tools. PHOTO: UNSPLASH
As surgical robotics companies expand beyond domestic markets, regulatory approvals are becoming a critical part of global growth. Companies are no longer competing only on hardware and clinical performance. They are also competing on their ability to enter tightly regulated healthcare systems and build long-term hospital partnerships.
Hong Kong-based Cornerstone Robotics is now moving further into that phase of expansion after its Sentire Endoscopic Surgical System received CE Mark certification under the European Union’s Medical Device Regulation framework.
The approval allows the company to commercialize the system across European markets for minimally invasive procedures in general surgery, gynecology, thoracic surgery and urology. For surgical robotics companies, regulatory approvals often represent more than product validation. They also determine market access, hospital adoption opportunities and long-term commercial scale.
Cornerstone Robotics has already been building clinical operations in the UK ahead of the approval. Since 2025, the company has worked with Portsmouth Hospitals University NHS Trust on clinical investigations involving the Sentire Surgical System. According to the company, the system has been used across procedures involving urology, gynecology and gastrointestinal surgery. The company says the clinical investigation helped generate real-world data to support physician training, research and future adoption efforts.
Alongside the regulatory approval, Cornerstone Robotics is also expanding its local operations in Europe. The company established a UK subsidiary in 2025 and has been developing training, clinical support and after-sales service capabilities for hospitals using the system.
That operational buildout reflects a larger challenge inside surgical robotics. Hospitals adopting robotic systems often require ongoing clinical training, technical support and workflow integration alongside the hardware itself.
Cornerstone Robotics says its strategy centers around vertically integrated development across engineering, software, imaging and robotics systems. The company argues that this structure gives it greater control over product development, supply chain management and long-term operational stability.
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, said: "Receiving CE Certification marks a major milestone in Cornerstone Robotics' evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."
The CE approval also comes several months after the company completed an oversubscribed financing round of approximately US$200 million in November 2025.
The funding and regulatory expansion together signal how surgical robotics companies are increasingly entering a more commercially focused stage of growth. Beyond research and development, companies are now investing more heavily in regulatory approvals, hospital partnerships, physician training and international operational infrastructure as competition expands across global healthcare markets.
Keep Reading
Connecting Chinese innovation with global markets through capital, collaboration and real-world deployment opportunities
Updated
March 30, 2026 2:29 PM
A Train Of Hong Kong's Mass Transit Railway (MTR) Metro System at Sunny Bay. PHOTO: ADOBE STOCK
As global tech ecosystems become more interconnected, the ability to move innovation across borders is becoming just as important as building it. A new partnership between MTR Lab, the investment arm of MTR Corporation and ZGC Science City Ltd, a government-backed technology ecosystem based in Beijing’s Haidian district, reflects this shift.
At its core, the collaboration is designed to connect high-potential Chinese startups with global capital, real-world deployment opportunities and international markets. It focuses on sectors like AI, robotics, smart mobility and sustainable urban development—areas where China already has strong technical depth but where scaling beyond domestic markets can be more complex.
This is where the partnership begins to matter. ZGC Science City sits at the center of one of China’s most concentrated innovation clusters, with thousands of AI companies and a growing base of specialised and high-growth firms. MTR Lab, on the other hand, brings access to international markets, industry networks and practical deployment environments tied to infrastructure, transport and urban systems. Together, they are attempting to bridge a familiar gap: turning local innovation into globally relevant products.
In practice, the model is straightforward. ZGC Science City will introduce MTR Lab to startups working in priority sectors, creating a pipeline for potential investment and collaboration. From there, MTR Lab can support these companies through funding, pilot projects and access to overseas markets. The idea is not just to invest, but to help startups test and apply their technologies in real-world settings, particularly in complex urban environments.
The timing is notable. China’s AI and deep tech ecosystem has expanded rapidly, with thousands of companies contributing to advancements in automation, smart infrastructure and sustainability. At the same time, global demand for these technologies is rising, especially as cities look for more efficient and scalable solutions. Yet, moving from innovation to adoption often requires cross-border coordination—something individual startups may struggle to navigate alone.
This partnership also builds on a broader pattern. Corporate venture arms like MTR Lab are increasingly positioning themselves not just as investors, but as connectors between markets. By combining capital with access to infrastructure and deployment scenarios, they offer startups a way to move faster from development to real-world use. For ZGC Science City, the collaboration adds an international layer to its ecosystem, helping local companies extend beyond domestic growth.
What emerges is a model that goes beyond a typical investment announcement. It reflects a growing recognition that innovation today is rarely confined to one geography. Technologies may be developed in one ecosystem, refined in another and scaled globally through partnerships like this.
As cross-border collaboration becomes more central to how startups grow, partnerships like the one between MTR Lab and ZGC Science City point to a more connected innovation landscape—one where access, not just invention, defines success.